The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

The legal developments around ranitidine have been closely watched ... In other recent news, GlaxoSmithKline (NYSE:GSK) has reported notable developments. GSK's investigational biologic ...

GlaxoSmithKline didn't admit liability in ... involuntary recall of Zantac and other heartburn medications containing ranitidine, after discovering the presence of a possible carcinogen.

GlaxoSmithKline Pharmaceuticals Limited is ... In the year 1988, the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also, they started a joint venture project with ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.